First in Human Study of TORL-1-23 in Participants With Advanced Cancer
NCT05103683
This study is recruiting at 9 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Solid Tumor
- Ovarian Cancer
- Endometrial Cancer
- NSCLC
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- TORL Biotherapeutics, LLC
- Last updated on ClinicalTrials.gov
- February 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Providence Medical Foundation · Fullerton, CA
- UCLA - JCCC Clinical Research Unit · Los Angeles, CA
Kentucky · 1
- University of Kentucky Medical Center · Lexington, KY
Minnesota · 2
- University of Minnesota · Minneapolis, MN
- Mayo Clinic in Rochester · Rochester, MN
New York · 1
- Memorial Sloan Kettering Cancer Center · New York, NY
Ohio · 1
- Cleveland Clinic · Cleveland, OH
Texas · 1
- Sarah Cannon Research Institute Texas Oncology · Tyler, TX
Virginia · 1
- Virginia Cancer Specialists · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.